Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "outperform" rating re-affirmed by analysts at Wedbush.
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results